Mineralys Therapeutics Q2 net loss $12.1M; cash $282.8M; Advance-HTN enrollment on track

Mineralys Therapeutics, Inc.

2023-Q2 EPS reported -$0.77

Net loss of $12.1M for Q2 2023 vs $6.5M in Q2 2022, driven by increased R&D and G&A spend.
Cash, equivalents and investments $282.8M as of June 30, 2023, up from $110.1M at Dec 31, 2022.
R&D expenses $11.9M vs $5.6M YoY, reflecting initiation of lorundrostat pivotal program.
Advance-HTN Phase 2 trial enrollment ongoing; topline data expected 1H 2024.
Phase 3 Launch-HTN trial and Phase 2 CKD trial both expected to start in 2H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mineralys Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $12.1 million for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Net income: Net loss was $12.1 million for the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 7, 2023, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

Mineralys Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001933414-23-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.